DANVERS, Mass., and GLASGOW, UK (January 17, 2024) –
Beckman Coulter Genomics and Vitrology Ltd. today announced a
strategic partnership to offer customers a wide range of biosafety
testing services. The alliance provides the biopharmaceutical
industry with two inclusive sources for the full complement of
molecular, in vitro and in vivo genomic services necessary for the
identification, stabilization and purification of biological
products.
The alliance also provides customers with access to the next
generation sequencing technologies that are revolutionizing
biology. It is widely recognized that massively parallel
sequencing technologies hold incredible promise for the study of
DNA sequence variation in vaccines, cell banks and gene therapy
products, and allow the use of an open-question approach for the
safety characterization of biologics.
"Partnering with leading-edge innovators to respond to the
dynamic research needs of our customers worldwide is fundamental to
our goals as a quality genomic services provider," said Elena
Jouravleva, global product manager for Biologics Testing Services
at Beckman Coulter Genomics. "This alliance supplements
Beckman Coulter’s existing biologics testing services, which
have a focus on identity and stability testing, with
Vitrology’s expertise in biosafety testing, in both Good
Manufacturing Practice and Good Laboratory Practice
environments."
"We are pleased to partner with Beckman Coulter Genomics to
offer the global biotechnology industry an array of scientific
assays to fully characterize a wide range of biologics," said
Margaret Temple, CEO of Vitrology. "This dynamic new alliance
is a natural fit, coupling Beckman Coulter Genomics’
sequencing and marketing capabilities with the experience of the
Vitrology team to offer an expert source of safety testing with
sequencing data and analysis. Both companies are committed to
ensuring that they offer the appropriate range of assays to ensure
clients can achieve regulatory authority approval for product
safety."
Beckman Coulter Genomics provides Sanger and next generation DNA
sequencing, gene expression profiling, genotyping and biologics
testing services. The collaboration between Beckman Coulter
Genomics and Vitrology further expands and complements both
companies’ extensive biologics testing services portfolios,
which are available to clients worldwide. .
About Beckman Coulter, Inc.
Beckman Coulter, Inc., based in Orange County, California,
develops, manufactures and markets products that simplify, automate
and innovate complex biomedical tests. More than a quarter of
a million Beckman Coulter systems operate in laboratories around
the world, supplying critical information for improving patient
health and reducing the cost of care. Recurring revenue,
consisting of consumable supplies (including reagent test kits),
service and operating-type lease payments, represent about 80
percent of the company's 2009 revenue of $3.3 billion. For more
information, visit www.beckmancoulter.com or
www.beckmancoulter.com/75years.
About Vitrology Limited
Vitrology Limited is a contract testing organization based
in Glasgow, Scotland, providing GMP and GLP assays to detect
potential contaminants in biological products, as well as offering
regulatory and consulting services. The company has a highly
experienced team, whose members have tested a wide range of
biopharmaceutical, vaccine and veterinary products, from
pre-clinical to commercial stage, over a fifteen-year period. For
more information, visit www.vitrologybiotech.com.
Beckman Coulter and the stylized logo are registered trademarks
of Beckman Coulter, Inc.
SOURCE